# ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors

> **NCT04205227** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **ENB Therapeutics, Inc** · enrollment: 137 (estimated)

## Conditions studied

- Cancer
- Melanoma
- Ovary Cancer
- Pancreatic Cancer
- Solid Tumor

## Interventions

- **DRUG:** ENB003
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04205227
- **Lead sponsor:** ENB Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-02-18
- **Primary completion:** 2026-01-01
- **Final completion:** 2026-03-31
- **Target enrollment:** 137 (ESTIMATED)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04205227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04205227, "ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04205227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*